Results 221 to 230 of about 119,810 (307)

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi, Masami Kodama, Hana Inoue, Masato Konishi, Masami Sugihara, Takashi Murayama, Ryosuke Ishida, Koichiro Ishii, Shuichi Mori, Yukari Endo, Xi Zeng, Yukiko U. Inoue, Takayoshi Inoue, Satoru Noguchi, Hajime Nishio, Eri Nakashima, Norio Suzuki, Noriko Nakaya, Ryushi Sato, Yuya Otori, Ayuna Tsutsumi, Mirei Takahashi, Takayuki Oka, Haruo Ogawa, Kayoko Kanamitsu, Hiroyuki Kusuhara, Utako Yokoyama, Junko Kurokawa, Hiroyuki Kagechika, Takashi Sakurai   +29 more
wiley   +1 more source

Association Between <i>GRIN1</i> rs28489906 and Major Depressive Disorder and Treatment Response to Antidepressants in Patients with Type 2 Diabetes. [PDF]

Brain Sci
Rodríguez-Ramírez AM, Benitez-Valenzuela M, Alcántara-Garcés MT, Sanabrais-Jiménez MA, Zaragoza-Hoyos JU, Del Valle-Ramírez H, Hernandez-Romero V, Rojas-Martínez A, García-Ulloa AC, Camarena-Medellin B.   +9 more
europepmc   +1 more source

A Zeolitic Pyrimidine Framework (ZPF) Nanoplatform Co‐Delivers a DNAzyme and a Protein Prodrug for Cascade‐Activated Tumour Therapy

Cell Proliferation, EarlyView.
A zeolitic framework co‐delivers a DNAzyme and a protein prodrug to tumour cells and executes a self‐amplifying therapeutic cascade: the DNAzyme elevates tumour oxidative stress to activate a caged RNase A prodrug. This spatiotemporally controlled synergy converts a genetic input into potent enzymatic cytotoxicity, suppressing tumour growth.
Yan Huang, Xingjie Hu, Jinli Sun, Min Yin, Nan Chen   +4 more
wiley   +1 more source

Neuroplasticity-Driven Mechanisms and Therapeutic Targets in the Anterior Cingulate Cortex in Neuropathic Pain. [PDF]

Brain Behav
Xiong H, Li L, Li Y, Chen Y, Leng J, Chen T.   +5 more
europepmc   +1 more source

Human IDO2 exhibits unique binding affinities distinct to those of human IDO1

The FEBS Journal, EarlyView.
Although indoleamine 2,3‐dioxygenase 2 (IDO2) is highly homologous to IDO1, it displays markedly lower catalytic activity. We found that IDO2 binds L‐tryptophan (L‐Trp) in a flipped orientation stabilized by the IDO2‐specific residue His143. Replacement of His143 with the IDO1‐equivalent tyrosine restored an IDO1‐like binding mode and increased ...
Shunsuke Nogi, Ayumu Takahashi, So Murakami, Nami Adachi, Tina Fujimoto, Yohta Fukuda, Taku Yamashita, Tsuyoshi Inoue, Hirofumi Tsujino   +8 more
wiley   +1 more source

Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives. [PDF]

ACS Chem Neurosci
Aslan FS, Barut B, Ozturk S, Eyigurbuz T, Akyuz E.   +4 more
europepmc   +1 more source

Intermediate filaments link glutamate–aspartate transporter deficiency to cochlear synaptopathy

The FEBS Journal, EarlyView.
In a healthy ear, GLAST transporters in supporting cells clear excess glutamate to protect auditory connections. When GLAST is missing, glutamate accumulates and leads to the destruction of structural scaffolding within the postsynaptic nerve endings. This internal collapse causes a loss of synapses that are essential for hearing, ultimately resulting ...
Paul Emmerich Krumpoeck, Lukas David Landegger   +1 more
wiley   +1 more source

Role of serum complement C3 in blood-brain barrier injury and prognosis of anti-NMDAR encephalitis. [PDF]

BMC Neurol
Zhang J, Ling L, Xiang L, Li W, Yang L, Wang Z, Li Y, Yue W.   +7 more
europepmc   +1 more source

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels

Haemophilia, EarlyView.
ABSTRACT Introduction Valoctocogene roxaparvovec, an adeno‐associated virus (AAV)‐based gene therapy, enables endogenous factor VIII (FVIII) expression in patients with severe hemophilia A without the need for regular FVIII infusions. Long‐term follow‐up assesses durability, safety, and immune‐related challenges following gene therapy.
Kerstin Herbst, Behnaz Pezeshkpoor, Claudia Klein, Thilo Albert, Philipp Lutz, Christian Strassburg, Ulrich Spengler, Georg Goldmann, Johannes Oldenburg   +8 more
wiley   +1 more source